The Mayo Clinic Cancer Center (MCCC) Administration (CCA) supports the Director, Senior Leaders, Program Leaders, Shared Resource Directors, and members in advancing MCCC's mission through administrative management, centralized services and overall planning and evaluation. CCA has been led by the Deputy Director for Administration, Jane Welter, MBA, since 2014. She is supported by 3 site-specific Associate Directors: Benjamin Ziemer, MEd, at Mayo Clinic in Florida; Jenny Ho, MPH, MHSA, at Mayo Clinic in Arizona; and David Moertel, MBA, at Mayo Clinic in Rochester, MN. The CCA provides administrative support for all internal and external planning and evaluation efforts, including meetings of the Executive Committee, Research Committee, Clinical Research Committee, Internal Scientific Advisory Committee and the External Advisory Committee. As a matrix center, the CCA coordinates key staff involved with the CCSG and its ancillary activities. This includes 1) Financial administration, including oversight of grant, internal, and philanthropic funds; 2) Grants administration; 3) Management of internal and external collaborations; 4) Shared Resource oversight; 5) Clinical research support; 6) Communications; 7) Informatics; and 8) Space management. In the past funding period, CCA has assisted the Director and Senior Leaders in many efforts including the effort to update the MCCC strategic plan; revision of MCCC membership criteria; and orientation of 5 new Senior Leaders, 13 new Program Leaders, 4 new Shared Resource Directors and 3 new Associate Directors for Administration. CCA works with the Director to manage all MCCC funds, regardless of source, and provide financial oversight for activities such as Developmental Funds and Shared Resources. CCA has partnered with the Department of Development to obtain and manage philanthropic funds and has facilitated scientific collaborations with other Mayo Clinic Centers (Center for Clinical and Translational Science, Center for Individualized Medicine, Center for Regenerative Medicine) and with other institutions (University of Minnesota Masonic Cancer Center, University of Illinois Urbana-Champaign, University of Mississippi Medical Center, University of Central Florida, Florida State University, Arizona State University). CCA has been engaged in increasing support for clinical research at MCCC, for example by implementing an Early Cancer Therapeutics Unit, creating the Clinical Research Committee, and better aligning the Disease Groups with clinical trials. Future directions include continued support for the Director and Senior Leadership; strategic planning efforts; efforts to impact cancer disparities in our catchment area; expanding internal and external collaborations; developing a new tool to manage CCSG-related information; the implementation of a new clinical research management system; and the implementation of measurement of outcomes for career development awards.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications